Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
August 03, 2023 16:05 ET
|
Virios Therapeutics
ATLANTA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral...
Vielight Starts Clinical Trial to Study Photobiomodulation Device Treatment for Post-Covid Cognitive Impairment
July 26, 2023 10:33 ET
|
Vielight Inc.
Toronto, Canada, July 26, 2023 (GLOBE NEWSWIRE) -- Vielight Inc. announced it has commenced a new clinical trial in the United States to study how brain stimulation photobiomodulation (PBM)...
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study
July 17, 2023 07:05 ET
|
Virios Therapeutics
ATLANTA, July 17, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Daxor Corporation Announces a 49.4% Increase In Its Single-Use Diagnostic Kits Year-Over-Year and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
July 27, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, July 27, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today an unaudited increase of 49.4% in sales of...
DAXOR CORPORATION ANNOUNCES PARTNERSHIP WITH MEDAXIOM TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100®)
July 21, 2022 08:00 ET
|
Daxor Corporation
Daxor Has Exclusive Access to the Cardiovascular Industry's Most Comprehensive and Powerful Network of Executives and Clinicians - Sharing Best Practices, Guidance and Resources to Dramatically...
DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT PHASE II AGREEMENT WITH THE UNIFORMED ARMED SERVICES UNIVERSITY FOR THE DEVELOPMENT OF A NON-NUCLEAR BLOOD VOLUME ANALYSIS (BVA) DEVICE
June 27, 2022 08:00 ET
|
Daxor Corporation
New BVA Device Aims to Possess Gold Standard Accuracy and Reproducibility with Increased Safety, Access, Ease of Use, and Frequency of Testing Afforded by a Non-Nuclear Tracer Oak Ridge, TN, June ...
Daxor Corporation to Showcase the Benefits of BVA-100® Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 18th Annual Meeting
June 13, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, June 13, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will exhibit at the American...